法维皮拉维
病毒学
生物安全
生物
利巴韦林
病毒复制
病毒
反向遗传学
2019年冠状病毒病(COVID-19)
医学
疾病
生物技术
传染病(医学专业)
遗传学
基因
突变体
病理
丙型肝炎病毒
作者
Xianliang Ke,Chang Ye,Renyi Liu,Feng Liu,Quanjiao Chen
摘要
Nipah virus (NiV) is a deadly zoonotic pathogen with high potential to cause another pandemic. Owing to biosafety concerns, studies on living NiV must be performed in biosafety level 4 (BSL-4) laboratories, which greatly hinders the development of anti-NiV drugs. To overcome this issue, minigenome systems have been developed to study viral replication and screen for antiviral drugs. This study aimed to develop two minigenome systems (transient and stable expression) based on a helper cell line expressing the NiV P, N and L proteins required to initiate NiV RNA replication. Stable minigenome cells were resistant to ribavirin, remdesivir and favipiravir but sensitive to interferons. Cells of the transient replication system were sensitive to ribavirin and favipiravir and suitable for drug screening. Our study demonstrates a feasible and effective platform for studying NiV replication and shows great potential for high-throughput drug screening in a BSL-2 laboratory environment.
科研通智能强力驱动
Strongly Powered by AbleSci AI